Precision Medical Gene Sequencing Stocks
Precision Medical Gene Sequencing Stocks, which requires access to relevant information in order to answer the question, according to years of learning experience, if you answer the question of Precision Medical Gene Sequencing Stocks, it can make you twice as easy as twice as easy, and the following share the methodology experience related to Precision Medical Gene Sequencing Stocks, for your reference and reference.
Precision medical gene sequencing stocks
In 2021, precision medical gene sequencing stocks are as follows:
___Polyglossia: stock price rose more than 40% from the beginning of the year, the rate of increase led the A-share medical sector.
__ South Micro Medical: shares rose 17.4% from the beginning of the year.
__Auyang Health: shares rose 11.9 percent from the beginning of the year.
__Strong Medical: Shares up 9.4 percent from the start of the year.
__ Oriental Bio: shares up 60.27 percent.
__Daan Genetics: shares up 59.42 percent.
__Leopold Medical: Shares rose 51.41 percent.
__Yangpu Medical: Shares rose 40.9 percent.
__ Arch Medical: Shares rose 38.22 percent.
__ Wanbond: Shares rose 32.27 percent.
__Baoleit: Shares rose 31.17 percent.
__Ribon Instruments: shares rose 27.86 percent.
__Kenfan Bio: shares rose 26.47 percent.
__Nanlin Pharmaceuticals: shares rose 25.24 percent.
__ Hesid: shares rose 24.97 percent.
__Hestron Pharmaceuticals: shares up 24.76 percent.
__Chunli Medical: shares up 21.95 percent.
__Lanfan Medical: shares rose 19.57 percent.
__Heart Pulse Medical: Shares rose 17.99 percent.
__Enti Medical: Shares rose 17.29 percent.
__Myriad Medical: shares rose 16.08 percent.
__ Vanguard Medical: Shares rose 15.96 percent.
__ Jianhong Information: shares rose 15.83 percent.
__Gu Sheng Tang: Shares rose 15.58 percent.
__Witness Technologies: shares rose 15.37 percent.
__Mecon Bio: shares rose 14.85 percent.
__Wangeron: shares up 14.66 percent.
__Haitron Pharmaceuticals 2021 total revenue of about 118 million yuan, an increase of about 73.83% year-on-year; net profit of about 55.5739 million yuan, an increase of about 366.52% year-on-year.
__ Chunli Medical's total revenue in 2021 will be about 663 million yuan, representing a year-on-year increase of about 21.95%; net profit will be about 133 million yuan, representing a year-on-year increase of about 40.00%.
___Nanwei Medical is an innovative medical device company registered in Shanghai, which is dedicated to providing clinical medical institutions with a series of innovative products and professional solutions for the treatment of digestive system tumors. The company focuses on the research, development and industrialization of GI tumor diagnostic and treatment products related to GI endoscopy. The company's digestive tumor diagnostic and therapeutic product portfolio covers the whole industry chain of diagnosis, treatment and consumables. Based on the dual-core strategy of "intervention + endoscopy", the company has laid out its product portfolio in the areas of "intervention", "ultrasound endoscopy" and "disposable endoscopy". The company has laid out a complete product line with "intervention", "ultrasound endoscopy" and "disposable endoscopy" as the three cornerstones. The company's esophageal cancer diagnosis and treatment series products cover the whole process of endoluminal treatment, covering the whole industry chain from diagnosis, treatment to rehabilitation, and building an ecosystem of esophageal cancer diagnosis and treatment. The company adheres to the road of combining independent innovation and cooperative research and development, and has obtained a number of innovative achievements and invention patents. The company has developed and listed a number of innovative products, some of which fill the gaps in the field of high-end medical devices in China. The company went public on October 29, 2020 with stock code 688029.
___Wanbond was founded in 1983, formerly known as Fuyang Pharmaceutical, located in Huanshan Township, Fuyang District. The company is mainly engaged in the research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations, involving cardiovascular system, digestive system, anti-tumor system, nervous system drugs and other fields. The company adheres to the business philosophy of "market-oriented, science and technology-based, quality-fundamental, management-guaranteed". The company went public on October 29, 2020 with stock code 600645.
Gene sequencing medical concept stocks
Gene sequencing medical concept stocks in 2023 are:
1. Mindray Bio: the recent average cost is 71.86 yuan, and the stock price is running below the cost. The power of both the long and short sides is relatively balanced. Today, the stock rose, indicating that the market for the stock's attention is higher, short-term operation, investors can be appropriate amount.
2. Saili medical: recent average cost of 11.22 yuan, the stock price is running below the cost. The power of both sides is relatively balanced. Today the stock stopped, indicating that the market for the stock of concern is higher, short-term operation, investors can be moderate.
3. Baolite: recent average cost of 19.09 yuan, the share price is running below the cost. The power of both sides is relatively balanced. Today, the stock rose, indicating that the market for the stock's attention is higher, short-term operation, investors can be moderate.
4. Lan Wei Medical: Lan Wei Medical's recent average cost is 14.11 yuan, the stock price is running below the cost. The power of both sides is relatively balanced. Today, the stock rose, indicating that the market for the stock's concern is higher, short-term operation, investors can be appropriate amount.
5. Daan shares: the recent average cost of 18.48 yuan, the share price is running below the cost. The power of both sides is more balanced. Today the stock stopped, indicating that the market for the stock of concern is higher, short-term operation, investors can be moderate.
The above is part of the 2023 gene sequencing medical concept stocks, investment risk, the market need to be cautious.
Gene sequencing precision medicine stocks
Listed companies related to gene sequencing and precision medicine include:
__ Squire Sanders Pharmaceuticals: a national key high-tech enterprise with a state-recognized enterprise technology center, a postdoctoral scientific research station, the Shenzhen Genome Drugs Engineering Laboratory, the Shenzhen Key Laboratory of Enzyme Coupled Biotechnology, and so on. Technology Key Laboratory, etc. It is a high-tech enterprise integrating R&D, production and sales of new drugs.
__Leipu Medical: the largest cardiovascular medical equipment R & D and manufacturing base, the company is mainly engaged in cardiac implantation interventional diagnosis and treatment and surgical medical equipment research and development, production and sales.
___Bao Lite: the national torch plan key high-tech enterprises, with a nationally recognized enterprise technology center, national enterprise postdoctoral research station, Guangdong Province, vascular surgery engineering technology research and development base and other professional platforms.
In addition to this, you can also pay attention to the listed companies such as UWG, Wantai Biologicals, Mike Biologicals, Antu Biologicals, Meikang Biologicals, Shuoshi Biologicals, Qujiangdong and so on. Please note that the above information is for reference only, investment risk, decision-making needs to be cautious.
Medical device gene sequencing concept stocks
Medical device gene sequencing concept stocks in 2021 are:
1. Lepu medical: its shareholding company Shenzhen Huada Ingenuity Science and Technology Co. Ltd. developed nasal spray new crown vaccine has been approved for emergency use.
2. Daan Gene: the company's equity subsidiary Guangzhou Wanfu biological kit (fluorescent PCR method) new coronavirus (2019-nCoV) antigen detection card (only for self-testing) has been approved for registration by the State Drug Administration.
3. Baoan Bio: on April 16, 2021 interactive platform said that the company's new coronavirus antigen detection kit has been certified by the European Union CE.
4.Dazhi Technology: the company developed a lung function meter, which is a medical device.
5. Myriad Healthcare: The State Key Laboratory of Life Information and Support (hereinafter referred to as the "State Key Laboratory"), an industry-university-research platform, has been completed and put into use in Shenzhen.
6. Shengxiang Bio: In 2020, the company will develop a fully automated nucleic acid testing platform (P2+P3) with a daily production capacity of 500,000 tubes, which has the advantages of short time-consumption, low cost, and easy operation.